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The number of options available to drug discovery scientists to enhance the solubil-
ity of poorly soluble compounds by conventional formulation approaches is limited. In
most cases, drug formulation is oriented toward the creation of a supersaturated solution
upon contact with aqueous environment, often combined with solubilizing agents and
precipitation inhibitors. The most popular formulations for achieving this target are the
lipid-based formulations called self-emulsifying and self-microemulsifying drug delivery
systems, SEDDS and SMEDDS, respectively. They offer enhanced absorption and hence
enhanced oral bioavailability of lipophilic drugs, presenting the drug in solubilized form
in vivo, avoiding dissolution, which can be the rate limiting step in drug absorption for
sparingly soluble drugs. The production of high energy or rapid dissolving solid state
formulations using drug particle engineering to enhance drug solubility and bio-
availability is also applied. These formulations include solid dispersions, nanoparticles,
co-ground mixtures etc. Furthermore, the development of prodrugs is also a useful strat-
egy to improve the physicochemical, biopharmaceutical or pharmacokinetic properties of
pharmacologically potent compounds, and thereby increase the developability and use-
fulness of a potential drug. Up to now, most medications were made for adults and chil-
dren’s requirements were not taken into account. Since the recent adoption of Paediatric
Regulations in the U.S. and E.U., there is a greater demand for age-appropriate medi-
cines for children. The challenges in paediatric formulation development are mostly as-
sociated with the difficulty in defining design requirements for the intended dosage form
that is most appropriate for the target patient population, due to the diversity of the pae-
diatric population (range of ages, physical size and capabilities) that varies significantly
from birth to age 12 yrs old along with the dosage flexibility. The last years there has
been an effort to develop solid paediatric formulations that deliver the appropriate dose
in a “user friendly” way and to find alternative drug delivery vehicles, such as mini-tab-
lets, dairy products, and new taste masking techniques in order to improve drug accept-
ability. In addition, alternative routes of administration have been proposed such as inha-
lation and nasal administration.
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Introduction
The majority of pharmacologically active new
chemical entities exhibit extremely poor aqueous
solubility (less than 10 M or 5 g/mL for a com-
pound with a molecular weight of 500)1 and good
permeability, and these characteristics result to low
bioavailability. The number of options available to
drug discovery scientists to enhance the solubility
of a compound by conventional formulation ap-
proaches, is limited. In case of ionizable com-
pounds the identification and selection of stable
pharmaceutical salts is the most popular technique2.
Other common strategies include the reduction of
solid particle size by micronization, such as mill-
ing3, or the formation of nanosuspensions,4 the use
of complexation agents such as cyclodextrins,5 or
the use of solubilizing excipients.6 In most cases,
the formulation of poorly water soluble compounds
is oriented toward the creation of a supersaturated
solution upon contact with aqueous environment,
often combined with solubilizing agents and precip-
itation inhibitors.3 The main target of such formula-
tion is to present the drug in supersaturated concen-
tration for an extended period of time, achieving
maintenance of the drug’s concentration in high
levels.
The most popular formulations for achieving
this target, are the lipid-based formulations, such as
self-emulsifying and self-microemulsifying drug
delivery systems (SEDDS and SMEDDS, respec-
tively) oil solutions. They offer enhanced absorp-
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tion and hence enhanced oral bioavailability of
lipophilic drugs7. These formulations present the
drug in solubilized form in vivo, avoiding dissolu-
tion, which can be the rate limiting step in drug ab-
sorption for sparingly soluble drugs.8,9 As the ab-
sorption of poorly water-soluble drugs is substan-
tially enhanced by coadministration with food rich
in triglycerides there have been developed lipid sys-
tems mimicking the solubilization provided by
foodstuffs.10,11 Moreover, the latest trend is the ef-
fort to develop paediatric formulations that deliver
the appropriate dose in a “user friendly” way, find-
ing alternative drug delivery vehicles that enhance
solubility and bioavailability, such as dairy prod-
ucts.12 The main characteristic of a successful lipid
formulation is the ability to maintain the drug in so-
lution in the stomach and throughout the intestine.
This is extremely challenging, as the majority of
poorly soluble drugs are more soluble in formula-
tions as they are diluted, while they precipitate after
dispersion of the drug in the intestine.
This large group of formulations, called lipid
formulations, have common characteristics, but
they can be differentiated by the extent to which
they disperse in water and their digestibility, rang-
ing from a simple oily formulation dispersed by di-
gestion in the small intestine through to more com-
plex self-emulsifying and microemulsion systems.
Lipid systems generally include triglycerides, mono
and diglycerides, lipophilic surfactants, hydrophilic
surfactants and cosolvents; excipients with a wide
variety of physicochemical properties. The lipid
formulation classification system (LFCS) was first
proposed by Pouton in 200013, providing a frame-
work for comparing formulations which in practice
could include a wide variety of different excipients.
The formulations are categorized in four types.
Type I includes formulations which are oils (tri-
glycerides or mixed mono and diglycerides) and re-
quire digestion to facilitate dispersion. Type II for-
mulations, are self-emulsifying, have no water solu-
ble components and produce relatively coarse emul-
sions in the 0.25–2 mm range. These are mostly oils
and water insoluble ester ethoxylates (nonionic sur-
factants with HLB values of approximately 11).
Type III formulations include water-soluble compo-
nents and produce very fine dispersions (<100 nm,
optically clear). They can be subdivided into Type
IIIA and IIIB, based on the proportion of water-sol-
uble surfactants and cosolvents that include. Type
IV formulations were included in lipid formulation
classification system (LFCS)14 in 2006. They do not
contain any lipid and produce fine micellar solu-
tions depending on the surfactant concentration.
There are many studies that point out the sig-
nificance of the dispersion phase for poorly wa-
ter-soluble drugs. Depending on the composition of
the lipid-based formulation, the drug is maintained
in solution in the lumen of the gastrointestinal tract
prior to absorption, after dispersion and during di-
gestion of the formulation.15 For example, the study
published by Mohsin et al. in 2009 about feno-
fibrate15 (Class II drug), demonstrated that Type II
and Type IIIA formulations often maintained the
drug in a supersaturated state for several hours after
dispersion, but Type IIIB and Type IV formula-
tions, which contained a higher proportion of wa-
ter-miscible excipients, typically lost solvent capac-
ity quickly on dispersion.
Supersaturated in vitro solubility
and dissolution data
Recent studies dealing with kinetic solubility
and supersaturated phenomena16,17 place particular
emphasis on the relevance of supersaturated solu-
bility with the absorption of orally administered
drugs and their biopharmaceutic classification.
Moreover, supersaturated solubilities are frequently
found in studies measuring drug concentrations in
human aspirates18,19 while the subsequent precipita-
tion of drug has been the subject of several stud-
ies.20,21 Recently, a study22 of the effect of super-
saturation on oral drug absorption revealed that for-
mulation technology that can induce super-
saturation may be of great assistance to the success-
ful development of poorly water-soluble drugs. In
the same vein, stable supersaturated milk based for-
mulations of NSAIDs were prepared with satisfac-
tory in vivo performance.12
Studies dealing with supersaturated dissolution
data for poorly water-soluble drugs are roughly di-
vided into two categories. In the first set of the
studies, the preparation of a high energy meta-sta-
ble form in an amorphous or semi-crystalline state
is described.23,24 Usually, the solubility of the amor-
phous polymorphs is much higher than that of its
crystalline form.24 This results in an increased dis-
solution rate and an enhancement of bioavailabity.25
However, it is not uncommon to observe a progres-
sive diminution of drug concentration during the
dissolution process due to the kinetic instability of
the high energy amorphous drug.26,27 This type
of studies of the enhanced solubility-dissolution
rate is routinely explained via the increased satura-








C Cs ( ) (1)
where D is the diffusivity, A is the specific area of
the particles, h is the diffusion layer path length in
the boundary layer about the particle, Cs is the solu-
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bility of the drug, and C is the concentration of
drug in solution at time t.
In the second set of studies, the dissolution of
poorly soluble drugs is studied in the presence of
various additives e.g. surfactant agents, polymers,
food constituents.28–30 An initial very high dissolu-
tion rate is usually observed which leads to concen-
tration values higher than the solubility level. When
these higher than saturation solubility values are
maintained and are justified by independent solubil-
ity experiments in the presence of additives, the
high rate of dissolution can be explained on the ba-
sis of Eq.1. However, in several studies the super-
saturated levels subsequently relax towards the sat-
uration solubility.31 This type of non-monotonic
dissolution curves cannot be explained using the
classical diffusion layer model. Instead, the reaction
limited model of dissolution seems to be more
appropriate to interpret these data. The model relies
on the bidirectional chemical reaction of the solid
species s with n free solvent molecules w, yielding










where k1 and k-1 are the forward and backward
microconstants. The major characteristic of this
model is that the rate of dissolution is not governed
by the saturation solubility. In this model, the satu-
ration solubility of the drug, Cs in the dissolution
medium is the result of the chemical equilibrium of
reaction 2 and corresponds to the concentration at















where V is the volume of the dissolution medium
and k1
* is a composite rate constant related to k1.
The rate of the dissolution process is given by
the velocity of the unidirectional reaction 2 and is





















where C is the concentration of the dissolved drug,
k1
*= k1[w0]
b, M0 is the initial quantity (dose) in mass
units,  and b are constants related to stoichiometry
of the reaction and also to the geometry of the parti-
cles.
Although in the original work29 k1
* was as-
sumed to be constant, a time dependant expression
of the following form may also be appropriate:
k K t h1
*    (5)
Expressions of this form have been used before
to account for time variable rate coefficients, due to
understirring and crowding in the microenviroment
of the reaction.30,31 This approach is often referred
to as fractal kinetics and has implications and phys-
ical meaning beyond an empirical time dependant
coefficient. In order to avoid infinity at time zero a
similar to Eq. 5 expression is considered:
k K g t h1 1
* ( ( ) )    (6)
where K is a constant while g is a constant prohibit-
ing the entire expression to approach zero for large
times.
Equations 4 and 6 describe a dissolution pro-
cess in which the equilibrium and therefore solubil-
ity as given by equation 3 is initially higher and
drops with time.32
“Supersaturated” drug delivery systems
The most commonly used approach to enhance
oral bioavailability of poorly soluble drugs, is to
administer the drug in solution in order to escape
the dissolution process step. To this end various
solubilizing agents are used such as oils, surfac-
tants, hydrophilic co-solvents and complexing mol-
ecules e.g. cyclodextrins to solubilize the poorly
water soluble drug3,33–36. An important approach is
the self-emulsifying or self-micro-emulsifying drug
delivery systems (SEDDS, SMEDDS), consisting of
a combination of oils with co-solvent and/or surfac-
tants to form oil-in-water emulsions or micro-emul-
sions where the drug is completely dissolved.3,37–40
The most notable example of commercially avail-
able “micro-emulsion formulation” is the cyclospo-
rine formulation Neoral®. The concentration of drug
in the microemusion (5000mg/50mL) is 100 mg/mL
(www.pharma.us.novartis.com/product/pi/pdf/neoral.pdf)
which is more than 10000 times higher than its
aqueous solubility (7.3 × 10–3 mg/mL, 37°C).36
Self-microemulsifying drug delivery systems of
Class II drugs like itraconazole,37 paclitaxel38 and
fenofibrate39 have been also reported in literature.
However, by entering the gastrointestinal (GI) tract
drug may precipitate from SEDDS. The capacity of
GI fluids to keep the drug in solution is an indicator
of the success of the SEDDS. In addition, in the
case of very lipophilic drugs, despite successful
solubilization, the free drug concentration may be
very low to result in significant intestinal ab-
sorption and systemic exposure. A more recent
approach is the supersaturated SEDDS (S-SEDDS)
which attempt to generate high supersaturated free
drug concentrations in the gastrointestinal tract
and to reduce drug precipitation rate allowing for
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sufficient absorption.3,40 S-SEDDS contain reduced
amount of surfactant and a precipitation inhibitor
such as hydroxyl-propyl-methylcellulose (HPMC).
The first drug formulated as S-SEDDS is paclitaxel
with an aqueous solubility <1 g/mL. The S-SEDDS
of paclitaxel contains less surfactant (cremophor®
EL) than the solubilized formulation Taxol® and
the precipitation rate of the drug is reduced by
the incorporation of 5% HPMC in the formula-
tion.40
In addition to SEDDS, a number of solid state
formulation drug delivering systems have been de-
veloped, that can induce supersaturated drug con-
centrations in the GI tract. These systems incorpo-
rate drug in a high energy (HE) or rapidly dissolv-
ing form (RDF).41 The production of HE or RDF of
a drug requires drug particle engineering such as
milling, cogriding, melting, freeze-drying etc. in or-
der to alter the size, morphology and/or wettability
of drug particles.42 Reduction of particle size, in
conjunction to improved wettability, usually results
in enhanced dissolution rate by increasing the avail-
able for dissolution drug surface area which also
leads to increased apparent drug solubility (i.e. the
equilibrium between drug in solution and a solid
form of the drug that is not in the most stable
state.42,43
Supersaturated solid drug formulations include
solid dispersions, nanoparticles, co-ground mix-
tures, crystalline salt forms of the drug, water solu-
ble prodrugs and the use of inorganic carrier based
delivery systems.
Solid dispersions contain the drug in the amor-
phous state dispersed in a hydrophilic polymeric
matrix such as polyvinylpyrolidone (PVP), hydroxy-
propyl methyl cellulose (HPMC), polyethylene-
glycole (PEG), or combination of polymers, as well
as surfactants such as Gelucire,® poloxamer 407
etc. Such a formulation, intend to produce high or
supersaturated intraluminal drug concentration by
increasing the drug apparent solubility. The initial
degree of supersaturation is in most cases depend-
ent on drug loading, polymeric matrix composition
as well as method of preparation, while the duration
of supersaturation depends on the presence of pre-
cipitation inhibiting agents in the co-dissolving
with the drug polymeric matrix. HPMC has been
used as polymeric matrix for the molecular disper-
sion of itraconazole (Sporanox®) and the solid dis-
persion of tacrolimus in an amorphous state. Super-
saturated concentrations were maintained for 4h
and 24h, respectively in biorelevant media.6,46,47
It is also possible to incorporate nanoparticles
into the conventional solid dispersion systems.
When possible, the use of nanoparticles, increase
the available for dissolution surface area and en-
hance furthermore the apparent solubility of the
poorly water soluble drug and the ability to form
supersaturated solutions.
Co-ground mixtures are often used as an alter-
native to avoid the problem of thermodynamic
instability of the amorphous-based dosage forms
used to formulate poorly water-soluble drugs. In
co-ground mixtures the crystalline form of the drug
is used, mixed and co-grinded with pharmaceutical
excipients such as lactose and HPMC. This proce-
dure often results in limited supersaturation that
may significantly increase oral bioavailability of
poorly water soluble drugs.46
Inorganic materials, have also gain great atten-
tion as possible carriers for poorly water soluble
drugs.47,48 Recently, an ordered mesoporous silica
(OMS) based delivery system of itraconazole was
developed by Mellaerts et al.49 The formulation
contains molecularly dispersed itraconazole into the
cylindrical pores of OMS. Supersaturated itraco-
nazole solutions were obtained when drug release
from OMS in simulated gastric fluid was studied,
that remained constant for at least 4h even when
dissolution medium was turned to simulated intesti-
nal fluid.
Crystalline salt forms of weak acids and bases
and pro-drugs with improved solubility and dissolu-
tion characteristics have been also used as strategies
to enhance oral absorption of poorly water soluble
drugs. Examples of the first case are several
non-steroidal anti-inflammatory drugs, e.g. diclo-
fenac, celecoxib, nimesulide, that are administered
in the crystalline potassium or sodium salt form, be-
ing more than 90% bioavailable compared to their
free acid form. However, the use of salt formation
requires an ionizable group and, therefore, this is
not a viable option for neutral compounds or those
with ionization constants that do not fall within the
physiological range.
The development of pro-drugs i.e. chemically
modified versions of the pharmacologically active
agent that must undergo transformation in vivo to
release the active drug, is also a useful strategy to
improve the physicochemical, biopharmaceutical
or pharmacokinetic properties of pharmacologically
potent compounds, and thereby increase the develo-
pability and usefulness of a potential drug.50–52 The
water-soluble oral pro-drug of the non-steroidal
anti-inflammatory drug sulindac, is an example of
this strategy. Sulindac is formulated as a pro-drug
that contains the inactive sulphoxide form which
gives the active sulphide form after oral absorp-
tion.53,54 The sulfoxide form pro-drug, is about
100-times more water-soluble than the pharmaco-
logically active sulphide. The greater solubility of
the pro-drug in conjunction to its optimal lipo-
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philicity (logP 1.52 at pH 7.4) provides more effi-
cient oral absorption.53,54
Phosphate esters can increase the oral bio-
availability of many poorly water-soluble drugs.
They are especially useful for drug candidates that
require a high dose and exhibit a dissolution-rate
limited absorption.52 Nearly all oral phosphate ester
pro-drugs are rapidly hydrolyzed to the parent drug
by endogenous alkaline phosphatases at the intesti-
nal cell surface during absorption, leading to low
pro-drug concentrations in the systemic circulation.
An example of water-soluble phosphate ester is
fosamprenavir (Lexiva/Telzir; GlaxoSmithKline),
the phosphate ester of the HIV protease inhibitor
amprenavir (Agenerase; GlaxoSmithKline), which
shows improved water solubility and an oral bio-
availability that is equivalent or higher to that of
amprenavir.55 However, the poorly water-soluble
amprenavir (0.04 mg per ml) requires a high dose
(1,200 mg twice a day, or 8 capsules), while
fosamprenavir has a 10-fold higher water solubility,
permitting a more patient convenient dosage regi-
men (4 tablets once a day).55,56 After administration,
fosamprenavir is rapidly hydrolyzed to amprenavir
by gut epithelial alkaline phosphatases during ab-
sorption and limited concentrations of the pro-drug
reach the circulation.56,57
Development of paediatric formulations:
a challenging task
Since the recent adoption of Paediatric Regula-
tions in the U.S. and E.U., there is a greater demand
for age-appropriate medicines for children. Even
though there is a growing demand, still paediatric
drug formulation science is at the beginning. The
reason why is because it is complex, multi-paramet-
ric, resource- and time-intensive. Developing such
formulations is a very challenging subject. There
are a lot of parameters that should be taken into ac-
count and there are still many open questions. Solid
dosage forms present some issues, as children have
difficulty swallowing whole solid drug carriers like
tablets or capsules. Moreover, providing age-appro-
priate doses at different strengths is a big issue,
while problems in dosing accuracy, stability, palat-
ability and unknown bioavailability of compounded
products exist in liquid forms. So, the challenges in
paediatric formulation development are mostly as-
sociated with the difficulty in defining design re-
quirements for the intended dosage form that is
most appropriate for the target patient population,
along with the dosage flexibility. Up to now, most
medications were made for adults and children’s re-
quirements were not taken into account. There are
also concerns about extemporaneous formulations,
especially around lack of dose accuracy, stability
and consistency in preparation.
This diversity drives the need for different for-
mulations, based on the needs and capabilities of
the target population, as well as a wide range of
dosage strengths within each formulation. The diffi-
culty in defining design requirements is mainly de-
rived from the diversity of the population that can
be encountered due to the range of ages, physical
size and capabilities of the paediatric population
that varies significantly from birth to age 12 yrs
old.
Defining design requirements for oral dosage
forms is primarily determined based on the age,
size and capability of the target population to swal-
low different sizes of dosage forms in order to ef-
fectively achieve dosing or acceptance of the dos-
age form. One main issue when designing paediat-
ric formulations is the volume of the liquid, which
has to be very small, especially if administered to
infants or the size of the capsule/tablet. This diver-
sity and range of ages also drives the need for a po-
tential large range of dosage strengths over the
range of ages defined by the target patient popula-
tion. When patients are over the age of 6 yrs old
there is better acceptance of small to medium tab-
lets intended for swallowing but there is at least a
relatively large percentage of the population that
still have difficulty swallowing tablets or capsules.
When children reach the age of 12 yrs, then most
patients can swallow a tablet or capsule of reason-
able size. After that age the difficulties in delivering
a solid oral dosage form decrease significantly and
the diversity in the population in this area of design
is decreased. When the age range of the target
population is from birth to 8 or 10 yrs of age
then the design requirements is generally compli-
cated.
For patients below 2 yrs of age, tablets or cap-
sules are not appropriate for swallowing as a whole
dosage form. In children less than 2 yrs of age, gen-
erally liquid dosage forms are widely acceptable
and in some cases orally disintegrating or film strip
type dosage forms could be acceptable. Between
the ages of 2 to 6 years of age the capability of a
child to swallow a small size tablet or capsule is
highly variable and many times based on ex-
perience. The EMA guidance states that tablets
should be not larger than 5 mm for patients less
than 6 yrs of age and this size can still be an issue
for swallowing in many patients. In order to
achieve acceptable dosing in the diverse population
encountered in this age range, it is recommended
that a liquid or orally disintegrating dosage form be
considered.
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’User friendly’ paediatric formulations
The last years there has been an effort to de-
velop solid paediatric formulations that deliver the
appropriate dose in a “user friendly” way and to
find alternative drug delivery vehicles, such as
mini-tablets, dairy products, and new taste masking
techniques in order to improve drug acceptability.
Oral pathway is the most common route of drug ad-
ministration, and a great progress has been recorded
in this area concerning paediatric formulations. Pel-
lets and generally small-sized dosage forms like
mini-tablets or sprinkles are very popular solid car-
riers which give the flexibility to be administered
alone or dispersed in food. Orodispersible drug for-
mulations which disintegrate within few seconds in
the oral cavity is a different approach of innovative
dosage forms, such as oral lyophilisates, orodispe-
rsible films and orodispersible tablets (ODTs).58
The combination of both approaches, small-sized
dosage forms and orodispersible formulations, led
to orodispersible mini-tablets,59 offering numerous
advantages for paediatric treatment over conven-
tional techniques.
For newborn infants and young children (be-
low 6 years old), liquid dosage forms are preferred
instead of solid oral dosage forms, because of swal-
lowing issues. It has been developed a modified
feeding bottle (Medibottle®) which delivers the
drug while the baby drinks milk or other drink. By
this way can be reassured that the whole drug
amount will be delivered to the baby. For the deliv-
ery of a single dose of small-sized pellets has been
developed the Dose Sipping Technology. With this
innovative technology children’s’ swallowing is-
sues could be overcome, as small-sized pellets are
incorporated in a straw and when the child holds
the straw in a beverage and by sipping, the drug is
delivered in a ‘user friendly’ way.60 An interesting
alternative drug delivery vehicle is milk. Milk,
which is a natural oil-in-water emulsion, is a
bio-medium familiar to infants and older children.
The development of supersaturated alkaline solu-
tions containing high concentration of acidic drugs
(e.g. NSAIDs) and then dispersing them into milk
is an interesting way to deliver drugs to children in
a ‘friendly’ way.12 Recently, another innovating for-
mulation has been developed, such as the ‘pill swal-
lowing cup’. This cup, which contains the appropri-
ate dose, is filled full with a beverage and then the
patient drinks the drug from the cup. It helps pa-
tients who have difficulty in swallowing tablets.61
Measuring spoons provide the appropriate
dose, for the forms that require administration with
a measuring device. With this technology, the use
of inappropriate devices avoiding, such as house-
hold spoons (teaspoons and tablespoons), which
can lead to inaccurate dosing.62,63 In case that larger
volumes of medicine are required (more than 5 mL)
then an alternative solution could be graduated
measuring cups. A disadvantage of these cups is
that it is likely to result in overdose due to their re-
stricted accuracy level. It has been found that oral
syringes provide more accurate results than dosing
spoons64,65 but for the correct filling of the syringe
clear instructions should be provided to avoid air
bubbles.
Medications that are administered via the in-
haled route are preferred for respiratory diseases.
The therapeutic aerosol is delivered directly to the
target with less systemic side effects. However,
there are numerous difficulties concerning the de-
velopment of paediatric inhalers. Children’s airway
anatomy and inhalation pattern is very different
compared to adults. This has to be taken seriously
into account when it comes to the development of
paediatric formulations.
Compliance is essential for therapy via the in-
haled route and a close monitoring of children’s in-
halation technique is needed. Pressurized metered
dose inhalers (pMDIs) are not appropriate for chil-
dren under the age of 6 years. Breath-actuated pres-
surized metered dose inhalers may be a more appro-
priate alternative, as they have a special mechanism
automatically releasing the aerosol during the inha-
lation, but children must be able to overcome the
actuation force threshold by inhalation.
Despite the fact that ultrasonic and jet nebulizers
require power and tend to be expensive are still
widely used. Dry powder inhalers (DPIs) are an al-
ternative solution to pMDIs. DPIs take advantage
of the patient’s peak inspiratory flow in order to de-
liver the drug into the system. One example is the
Babyhaler which has been recently developed and it
is a valve holding chamber especially designed for
the use in infants. Smaller and more portable de-
vices that have recently been developed61 are
AeroNeb® Go, MicroAirTM and I-Neb® AAD®.
When small doses of drug are required,
parenteral delivery provides precise and regulated
infusion rates, as in Type I diabetes. Recently, a
number of needle-free drug delivery devices have
been developed which deliver large molecules, such
as insulin, vaccines and growth hormone, under
high pressure through the skin. Such devices in-
clude J-Tip®, PharmaJet® and Bioject® delivery
systems, which reduce the discomfort or the patient
anxiety caused by needles. Nasal delivery is an-
other interesting and alternative route of drug deliv-
ery. ViaNaseTM and the OptiNoseTM nasal delivery
devices have been developed for children, although
nasal formulations are mainly focused on adults.
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Conclusions
In most cases, the formulation of poorly water
soluble compounds is oriented toward the creation
of a supersaturated solution upon contact with
aqueous environment, often combined with
solubilizing agents and precipitation inhibitors.
This is very effective for drugs formulated and in-
tended for adult administration. Up to now, most
medications were made for adults and children’s re-
quirements were not taken into account. However,
since the recent adoption of Paediatric Regulations
in the U.S. and E.U., there is a greater demand for
age-appropriate medicines for children. To this end,
the last years there has been an effort to develop
solid paediatric formulations that deliver the appro-
priate dose in a “user friendly” way and to find al-
ternative drug delivery vehicles, such as mini-tab-
lets, dairy products, and new taste masking tech-
niques in order to improve drug acceptability. In ad-
dition, alternative routes of administration have
been proposed such as inhalation and nasal admin-
istration.
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